# A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)

> **NCT00692458** · PHASE3 · WITHDRAWN · sponsor: **Merck Sharp & Dohme LLC**

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Comparator: odanacatib
- **DRUG:** Comparator: placebo

## Key facts

- **NCT ID:** NCT00692458
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-09
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn for administrative reasons
- **Last updated:** 2016-08-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00692458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00692458, "A Study to Assess the Effects of MK0822 in Reducing the Risk of Bone Metastasis in Women With Breast Cancer (0822-029)". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00692458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*